medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2022, Número 1

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (1)


Utilidad de la plasmaféresis terapéutica en pacientes críticos con disfunción orgánica

Figueroa SJA, Rodríguez PLD, Mamposo VJC

Idioma: Español
Referencias bibliográficas: 30
Paginas: 1-13
Archivo PDF: 284.28 Kb.


RESUMEN

Introducción: La aféresis terapéutica es el procedimiento que separa y remueve el plasma de la sangre total, con el objetivo de eliminar componentes considerados responsables patógenos de una enfermedad o de sus manifestaciones clínicas.
Objetivos: Analizar los aspectos generales de la aplicación de la técnica de plasmaféresis como alternativa de tratamiento en pacientes críticos con disfunción orgánica. Métodos: Se realizó una investigación bibliográfica-documental acerca del tema. Se consultaron fundamentalmente las bases de datos de SciELO y Pubmed de los últimos diez años. Análisis y síntesis de la información: Se describen los aspectos de la plasmaféresis, desde sus criterios de indicación; así como la aplicación del procedimiento en los pacientes con disfunción orgánica y sus resultados en la evolución del paciente.
Conclusiones: Con la utilización de la plasmaféresis se encontró mejoría de los parámetros clínicos y de laboratorio en la mayoría de los pacientes en disfunción orgánica al egreso de la unidad de cuidados intensivos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schwartz J, Padmanabhan A, Aqui N, Ohlow MA, Cozzi E. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher.2016;31:149-62.

  2. Ipe TS, Pham HP, Williams LA 3rd. Critical updates in the 7th edition of the American Society for Apheresis guidelines. J ClinApher. 2018;33(1):78-94.

  3. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study BMJ 2012;345:e4565 DOI: https://10.1136/bmj.e4565

  4. Greinacher A, Friesecke S, Abel P,Zhou F. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolyticuraemic syndrome: a prospective trial. Lancet.2018;378:1166-73.

  5. Rimmer E, Houston BL, Kumar A,Kellum JA. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and metaanalysis. Crit Care.2018;18:699.

  6. Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41:2209-20.

  7. Chang T, Tu YK, Lee CT, Lauer B. Effects of Polymyxin B Hemoperfusion on Mortality in Patients with Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis. Crit Care Med. 2017;45:e858-64.

  8. Fortenberry JD, Nguyen T, Grunwell JR Dale RC, Gorman MP. Thrombocytopenia-Associated Multiple Organ Failure (TAMOF) Network Study Group. Therapeutic Plasma Exchange in Children with Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience. Crit Care Med. 2019;47:e173-e81.

  9. Winters JL, Cooper LT, Ratcliffe NR, McLeod B. National Heart, Lung, and Blood Institute. State of the science symposium in therapeutic apheresis-Therapeutic apheresis in cardiovascular disease. J ClinApher.2016;30:183-7.

  10. Ohlow MA, Brunelli M, Schreiber M, Lauer B. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry. J Cardiol. 2017;69(2):409-16.

  11. Cozzi E, Colpo A, De Silvestro G. The mechanisms of rejection in solid organ transplantation. TransfusApher Sci. 2017;56:498-505.

  12. Thompson C, Kneen R, Riordan A, Chang T, Tu YK. Encephalitis in children. Arch Dis Child.2018;97:150-61.

  13. Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. CurrOpin Neurol. 2017;30:334-44.

  14. Llufriu S, Castillo J, Blanco Y, Nguyen T Kiss J Goldman J. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology. 2019;73(12):949-53.

  15. Balogun R, Kaplan A, Ward D, McLeod B. Clinical Applications of Therapeutic Apheresis. J ClinApher. 2015;25:250- 64.

  16. Ewald N Hardt P Hans-Ulrich K. Severe hypertriglyceridemia and pancreatitis: presentation and management. CurrOpinLipidol.2019;20:497-504.

  17. McLeod B. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemia. CurrOpinHematol.2007;14:647-54.

  18. Ipe, T. S, Pham, H. P, & Williams, L. A. (2018). Critical updates in the 7th edition of the American Society for Apheresis guidelines. Journal of Clinical Apheresis,33(1),8-94. DOI: https://doi.org/10.1002/jca.21562

  19. Sánchez A, Ward D. Therapeutic Apheresis for Renal Disorders. Sem Dialysis.2018;25:119-31.

  20. Szczepiorkowski Z Winters J Bandarenko N. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence- Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J ClinApher.2017;25:83-177.

  21. Okafor C Ward D Mokrzycki M. Introduction and Overview of Therapeutic Apheresis. J ClinApher.2010;25:240-9.

  22. Winters JL. Apheresis Medicine State of art in 2017: American Society for Apheresis fifth special edition of the Journal of Clinical Apheresis. J ClinApher.2017;26(5):239-42.

  23. Dobke M, Hunt JL, Purdue GF, Baxter CR. Effect of plasma exchange therapy on circulating fibronectin in burned patients. J Burn Care Rehabil. 2020;6:239-42.

  24. Donati L, Signorini M, Busnach G, Noe L, Mazza E. Prophylactic plasma exchange in burn treatment. Int J Tissue React. 2020;9:215-8.

  25. Klein MB, Edwards JA, Kramer CB, Nester T, Heimbach DM, Gibran NS. The beneficial effects of plasma exchange after severe burn injury. J Burn Care Res. 2019;30:243-8.

  26. Kravitz M, Warden GD, Sullivan JJ, Saffle JR. A randomized trial of plasma exchange in the treatment of burn shock. J Burn Care Rehabil 1989;10:17-26.

  27. McManus WF. Is there a role for plasmapheresis/exchange transfusion in the treatment of the septic burn patient? J. Trauma2000;24:S137-45.

  28. Neff LP, Allman JM, Holmes JH. The use of therapeutic plasma exchange (TPE) in the setting of refractory burn shock. Burns 2010;36:372-8.

  29. Ninnemann JL, Stratta RJ, Warden GD, Saffle JR, Weber ME. The effect of plasma exchange on lymphocyte suppression after burn. Arch Surg 2020;119:33-8.

  30. Pham TN, Cancio LC, Gibran NS. American Burn Association practice guidelines burn shock resuscitation. J BurnCare Res 2018;29:257-66.




2020     |     www.medigraphic.com